Joe Schroers-Martin MD
@schroersmartin.bsky.social
Assistant Professor at Stanford University - Lymphoma genomics, viromics, ctDNA
Pinned
When should we use it? The role of brentuximab vedotin in 2024
Abstract. The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphom
ashpublications.org
At a full capacity #ASH24 session on "Moving the Needle in Hodgkin Lymphoma" - please take a look at our education chapter on the current role of BV! ashpublications.org/hematology/a...
What a lovely article about Marian Melish, a true inspiration. jabsom.hawaii.edu/news-events/...
Dr. Marian Melish celebrates 50 years of medicine & research in Hawaiʻi | John A. Burns School of Medicine
Throughout her medical career, renowned infectious disease expert Dr. Marian Melish has been making key contributions in science. Whether it be making discoveries crucial to understanding Staphylococc...
jabsom.hawaii.edu
September 15, 2025 at 11:46 PM
What a lovely article about Marian Melish, a true inspiration. jabsom.hawaii.edu/news-events/...
Reposted by Joe Schroers-Martin MD
At a full capacity #ASH24 session on "Moving the Needle in Hodgkin Lymphoma" - please take a look at our education chapter on the current role of BV! ashpublications.org/hematology/a...
When should we use it? The role of brentuximab vedotin in 2024
Abstract. The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphom
ashpublications.org
December 7, 2024 at 5:31 PM
At a full capacity #ASH24 session on "Moving the Needle in Hodgkin Lymphoma" - please take a look at our education chapter on the current role of BV! ashpublications.org/hematology/a...